News

RedHill Biopharma’s RHB-102 (prevention of nausea and vomiting) advanced clinical trial has began

Published on February 15, 2012 in News.

RedHill Biopharma commences advanced clinical trial with RHB-102 (Nausea and Vomiting) (February 14 2012) RedHill Biopharma commenced advanced clincial trial with RHB-102 (Nausea and Vomiting) (February 14 2012) Hebrew

RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (Prevention of Nausea and Vomiting)

Published on February 13, 2012 in News.

RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (Nausea and Vomiting) Feb 12th 2012 RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (Nausea and Vomiting) Feb 12th 2012 (Hebrew)

RedHill Biopharma obtains a CTA approval from Health Canada to commence an advanced trial with RHB-102 (prevention of nausea & vomiting)

Published on February 7, 2012 in News.

RedHill Biopharma obtains a CTA approval to commence an advanced trial with RHB-102 (prevention of nausea & vomiting) (February 5th 2012) RedHill Biopharma obtains a CTA approval to commence an advanced trial with RHB-102 (prevention of nausea & vomiting) (February 5th 2012) Hebrew

Mr. Gilead Raday’s interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients)

Published on February 2, 2012 in News.

See Mr. Gilead Raday’s interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients): http://israel21c.org/health/daily-pill-to-vanquish-nausea-after-chemo

IntelGenx, RedHill’s Development Partner in RHB-103 (Migraine) Announces Health Canada Approval for Pivotal Trial

Published on January 2, 2012 in News.

IntelGenx, RedHill’s Development Partner in RHB-103 (Migraine) Announces Health Canada Approval for Pivotal Trial

Dr. Jeff Lehighton presents RedHill Biopharma on Bloomberg TV

Published on November 23, 2011 in News.

Please use the link below to watch Dr. Jeff Lehighton, RedHill Biopharma’s Chairman of the Advisory Board, on Bloomberg TV: http://www.bloomberg.com/video/80653140/

RedHill Biopharma engages with CRO for potential pivotal trial with RHB-102 (prevention of nausea & vomiting in cancer patients)

Published on November 4, 2011 in News.

RedHill engages with CRO for potential pivotal trial with RHB-102 (Prevention of Nausea Vomiting ) (Hebrew) RedHill engages with CRO in preparation for potential pivotal trial with RHB-102 (prevention of nausea & vomiting )

RedHill Biopharma appoints Prof. Colm O’Morain, MD as Lead Investigator for the European Phase III trial with RHB-104 (Crohn’s)

Published on October 25, 2011 in News.

RedHill appoints Prof O’Morain as Lead Investigator for the European Phase III clinical trial with RHB-104 (Crohn’s) Hebrew Redhill appoints Prof O’Morain as Lead Investigator for the European Phase III trial with RHB-104 – Crohn’s (October 24 2011)

RedHill Biopharma appoints Prof. David Y. Graham, MD as Lead Investigator for the US pivotal trial with RHB-104 (Crohn’s)

Published on October 6, 2011 in News.

RedHill Biopharma appoints Prof Graham as Lead Investigator for RHB-104 – Crohn’s (Hebrew) (October 5, 2011) RedHill Biopharma appoints Prof Graham as Lead Investigator for the US pivotal trial with RHB-104 – Crohn’s (October 5, 2011)

RedHill Biopharma Acquires Exclusive Rights to a MAP Bacterium Companion Diagnostic Test for its RHB-104 (Crohn’s)

Published on September 26, 2011 in News.

RedHill acquires exclusive rights to a diagnostic test for RHB-104 – Crohn’s (Sep. 19 2011)

News

News

Latest News